Skip to main content
    G

    Genelux Corporation Common Stock (GNLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.48
    +0.16 (+6.90%)

    Market Cap: $104.97M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(6/14)
    Avg Surprise
    -26.93%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.22 - $-0.18
    6 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.20+2.5%
    60d ago$-0.20+2.5%
    30d ago$-0.20+1.7%
    7d ago$-0.19-2.2%
    Current$-0.20
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.22
    Range$-0.27 - $-0.17
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.22---
    Sep 26EST
    		-$-0.20---
    Jun 26
    Reported Aug 13
    		$-0.21$-0.20-5.00%Miss-5.0%
    Mar 26
    Reported May 7
    		$-0.20$-0.20+0.00%Beat+4.8%
    Dec 25
    Reported Mar 19
    		$-0.24$-0.22-9.94%Miss+4.0%
    Sep 25
    Reported Nov 5
    		$-0.21$-0.23+8.70%Beat-10.5%
    Jun 25
    Reported Aug 7
    		$-0.20$-0.22+9.09%Beat+9.1%
    Mar 25
    Reported May 6
    		$-0.21$-0.24+12.50%Beat+27.6%
    Dec 24
    Reported Mar 28
    		$-0.25$-0.25+0.00%Beat+0.0%
    Sep 24
    Reported Nov 14
    		$-0.19$-0.19+0.00%Beat+5.0%
    Jun 24
    Reported Aug 14
    		$-0.22$-0.21-4.76%Miss+4.3%
    Mar 24
    Reported May 9
    		$-0.29$-0.21-38.10%Miss+45.3%
    Dec 23
    Reported Mar 29
    		$-0.25$-0.19-31.58%Miss-108.3%
    Sep 23
    Reported Nov 14
    		$-0.20$-0.15-33.33%Miss-66.7%
    Jun 23
    Reported Aug 14
    		$-0.23$-0.15-53.33%Miss-43.8%
    Mar 23
    Reported May 15
    		$-0.53$-0.16-231.25%Miss-
    Dec 22
    Reported Jan 26
    		$-0.12$0.00N/AMiss-
    Jun 22
    Reported Sep 19
    		$-0.12$0.00N/AMiss-
    Mar 22
    Reported Jun 29
    		$-0.16$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.88EV/EBITDAN/A
    Price/FCF-3.89xFCF Yield-25.72%
    Profitability
    Profit Margin0.00%Operating Margin-455275.00%
    ROE-177.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.39xQuick Ratio2.39x
    Trading Statistics
    Beta0.58Avg Volume256.49K
    52-Week High$8.5452-Week Low$2.29

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.51
    SMA 20$2.51
    SMA 50$2.58
    SMA 200$2.76
    EMA 10$2.49
    EMA 20$2.51
    EMA 50$2.59
    EMA 200$2.90

    MACD

    Line: -0.03Signal: -0.03Hist: -0.00

    ADX

    ADX: 11.6+DI: 13.0-DI: 20.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down16.0
    PSAR$2.63

    Bollinger Bands

    Upper Band$2.64
    Lower Band$2.38
    %B Position1023%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    47.3

    Momentum Oscillators

    Stoch %K30.4
    Stoch %D38.6
    Williams %R-52.9
    ROC (10d)-1.6%
    Momentum-0.04
    CCI (20d)-118.6
    MFI (14d)53.7

    Volatility Measures

    ATR (14d)$0.13(5.3%)
    StdDev (20d)0.06
    Hist Vol48.2%(High)

    Volume Flow

    VWAP$2.44
    OBV-5.8M
    AD Line-4.2M
    CMF (20d)0.117

    Volume Metrics

    Avg Vol (20d)234.3K
    Vol Ratio3.4x(High)
    VWMA (20d)$2.50

    Pivot Points

    R3$2.65
    R2$2.59
    R1$2.45
    Pivot Point$2.39
    S1$2.25
    S2$2.19
    S3$2.05

    Advanced Oscillators

    TSI-7.32
    Ultimate Osc52.5
    KST-21.74

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$8,000$0$0$0$896,000$0$0$8,000$1.46M$0
    Cost of Revenue$0$0$148,000$0$0$0$452,000$0$0$0$201,000$0
    Gross Profit$0$0$8,000$0$0$0$-227,000$0$0$8,000$-201,000$0
    Operating Expenses$9.64M$9.17M$9.42M$8.19M$7.79M$7.82M$9.75M$6.94M$6.89M$8.12M$7.00M$5.31M
    R&D$6.51M$5.78M$5.65M$4.74M$4.76M$4.70M$6.52M$4.05M$4.42M$4.01M$4.16M$2.82M
    SG&A$3.14M$3.39M$3.77M$3.45M$3.03M$3.12M$3.23M$2.89M$2.48M$4.11M$2.84M$2.49M
    Operating Income$-9,645,000$-9,171,000$-9,412,000$-8,194,000$-7,792,000$-7,816,000$-9,748,000$-6,941,000$-6,892,000$-8,115,000$-7,001,000$-5,307,000
    Interest Income$127,000$173,000$128,000$175,000$224,000$184,000$201,000$222,000$163,000$114,000$178,000$4,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$-167,000$0
    Income Before Tax$-9,471,000$-8,928,000$-9,247,000$-7,950,000$-7,456,000$-7,492,000$-8,976,000$-6,467,000$-6,576,000$-7,850,000$-6,656,000$-5,345,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,471,000$-8,928,000$-9,247,000$-7,950,000$-7,456,000$-7,492,000$-8,976,000$-6,467,000$-6,576,000$-7,850,000$-6,767,000$-5,345,000
    EBITDA$-9,634,000$-9,162,000$-9,315,000$-8,094,000$-7,634,000$-7,757,000$-9,120,000$-6,885,000$-6,854,000$-8,031,000$-6,968,000$-5,216,000
    EBIT$-9,598,000$-9,101,000$-9,375,000$-8,125,000$-7,680,000$-7,676,000$-9,177,000$-6,689,000$-6,739,000$-7,964,000$-7,001,000$-5,349,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GNLX

    News

    Genelux Corporation (GNLX) Stock Price, News & Analysis

    Genelux Corporation (GNLX) is a late clinical-stage biopharmaceutical company focused on developing oncolytic immunotherapies...

    Stock Titan•9/24/26•Neutral

    Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

    Genelux Corporation announced the publication of a case report demonstrating a deep and durable response in a patient with platinum-relapsed small cell lung cancer (SCLC) treated with systemically delivered...

    Yahoo Finance•9/10/26•Bullish

    Genelux chief scientific officer Yu Yong sells $26,658 of stock By Investing.com

    Genelux Corp's Chief Scientific Officer, Yu Yong, sold 9,683 shares of the company's common stock for $26,658 to cover tax obligations from restricted stock unit vesting. Following the transaction...

    Investing.com South Africa•9/3/26•Somewhat-Bearish

    Genelux CTO Joseph Cappello sells $28,112 in company stock

    Genelux CTO Joseph Cappello sold 10,257 shares of GNLX stock worth $28,112 on August 31, 2026, to cover estimated taxes from restricted stock unit vesting. Following the sale...

    Investing.com•9/3/26•Neutral

    Genelux CTO Joseph Cappello sells $28,112 in company stock By Investing.com

    Joseph Cappello, CTO of GENELUX Corp, sold 10,257 shares of company stock on August 31, 2026, for approximately $28,112 to cover estimated taxes. Following the sale...

    Investing.com South Africa•9/3/26•Somewhat-Bearish

    GNLX Valuation and Fair Value

    P/E
    -2.9x
    P/FCF
    -3.9x
    P/B
    6.9x
    See GNG's fair value

    GNLX Profitability: Margins, ROIC and FCF

    Operating margin
    -455275.0%
    Net margin
    0.0%
    ROE
    -177.9%
    FCF margin
    -358537.5%
    FCF yield
    -25.7%

    GNLX Competitors

    CompanyTicker
    Stereotaxis IncSTXS
    Definitive Healthcare CorpDH
    enGene Holdings Inc. Common StockENGN
    Vivani Medical Inc.VANI
    LENZ Therapeutics IncLENZ
    Armata Pharmaceuticals IncARMP
    Tonix Pharmaceuticals Holding CorpTNXP
    PDS Biotechnology CorpPDSB

    Sector: Healthcare

    GNLX Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    GNLX Bull Case vs Bear Case

    Bull case

    • 100.0% of GNLX's analyst ratings are Buy or Strong Buy.

    Bear case

    • GNLX beat EPS estimates in 37.5% of its last 8 reported quarters.
    • GNLX's quarterly revenue changed -95.3% year over year.

    GNLX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    1.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About GNLX

    Does GNLX pay dividends?

    Genelux Corporation Common Stock (GNLX) does not currently pay a regular dividend.

    What is GNLX's market cap?

    Genelux Corporation Common Stock (GNLX) has a market capitalization of $104.97M with a current stock price of $2.48.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In